C12N 2310/315
Phosphorothioates
C12N2310/315 (Phosphorothioates) appears on 3,465 US grants and 6,485 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,465
- Published applications
- 6,485
- Assignees
- 1,246
- Inventors
- 6,473
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 7 | 0 |
| 1994 | 5 | 0 |
| 1995 | 6 | 0 |
| 1996 | 31 | 0 |
| 1997 | 70 | 0 |
| 1998 | 62 | 0 |
| 1999 | 101 | 0 |
| 2000 | 128 | 0 |
| 2001 | 110 | 16 |
| 2002 | 115 | 78 |
| 2003 | 65 | 331 |
| 2004 | 52 | 319 |
| 2005 | 34 | 249 |
| 2006 | 42 | 135 |
| 2007 | 44 | 126 |
| 2008 | 39 | 84 |
| 2009 | 62 | 160 |
| 2010 | 94 | 149 |
| 2011 | 100 | 157 |
| 2012 | 113 | 151 |
| 2013 | 94 | 139 |
| 2014 | 112 | 173 |
| 2015 | 144 | 226 |
| 2016 | 132 | 241 |
| 2017 | 155 | 246 |
| 2018 | 163 | 247 |
| 2019 | 175 | 274 |
| 2020 | 177 | 314 |
| 2021 | 178 | 346 |
| 2022 | 182 | 430 |
| 2023 | 160 | 459 |
| 2024 | 173 | 536 |
| 2025 | 198 | 509 |
| 2026 | 138 | 390 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Antisense oligonucleotides for the treatment of stargardt disease29 Sep 2026US 12,747,440 B2ProQR Therapeutics II B.V.
- Optimized gapmers antisense oligonucleotides for increasing foxg1 expression8 Oct 2026US 2026/0308582 A1EliGab Tx LLC
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)8 Oct 2026US 2026/0308585 A1Alnylam Pharmaceuticals, Inc.
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996